QNCX insider transaction filings
Quince Therapeutics, Inc. — 27 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-15. Screen QNCX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-15 | 4 | Lamond David — Director | Grant/award (A): 2,700 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Senner Christopher J. — Director | Grant/award (A): 2,700 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Roberts Brigette — Chief Corp. Affairs Officer, Director | Grant/award (A): 34,675 (derivative) · Grant/award (A): 228,855 (derivative) · Grant/award (A): 124,830 (derivative) · Grant/award (A): 69,350 (derivative) · Grant/award (A): 362,092 (derivative) · Grant/award (A): 133,615 (derivative) · +3 more | EDGAR |
| 2026-01-23 | 4 | Hannah Brendan — CBO, COO & CCO | Grant/award (A): 365,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Thye Dirk — CEO and CMO, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Ryan Charles S. — President | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | McLoughlin Margaret — Director | Grant/award (A): 19,547 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Lamond David — Director | Grant/award (A): 29,423 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Bray June — Director | Grant/award (A): 18,724 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Senner Christopher J. — Director | Grant/award (A): 21,810 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Benatti Luca — Director | Sale (S): 50,000 @ $3.47 | EDGAR |
| 2025-12-29 | 4 | Benatti Luca — Director | Other (J): 8,918 | EDGAR |
| 2025-12-12 | 4 | Thye Dirk — CEO and CMO, Director | Gift (G): 739,885 @ $0 · Gift (G): 739,885 @ $0 | EDGAR |
| 2025-12-08 | 4 | Hannah Brendan — CBO, COO & CCO | Option exercise (M): 2,271 @ $0.55 · Option exercise (M): 25,280 @ $0.94 · Option exercise (M): 2,271 (derivative) @ $0 · Option exercise (M): 25,280 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Hannah Brendan — CBO, COO & CCO | Grant/award (A): 37,736 @ $1.20 · Grant/award (A): 37,736 (derivative) @ $0.12 | EDGAR |
| 2025-06-23 | 4 | Thye Dirk — CEO and CMO, Director | Grant/award (A): 150,944 @ $1.20 · Grant/award (A): 150,944 (derivative) @ $0.12 | EDGAR |
| 2025-06-23 | 4 | Ryan Charles S. — President | Grant/award (A): 7,548 @ $1.20 · Grant/award (A): 7,548 (derivative) @ $0.12 | EDGAR |
| 2025-06-06 | 4 | Lamond David — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | McLoughlin Margaret — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Bray June — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Senner Christopher J. — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Patni Rajiv — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Benatti Luca — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | RYAN UNA S — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Hannah Brendan — CBO, COO and CCO | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Thye Dirk — CEO AND CHIEF MEDICAL OFFICER, Director | Grant/award (A): 1,200,000 (derivative) @ $0 | EDGAR |
| 2025-02-11 | 4 | Ryan Charles S. — PRESIDENT | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Quince Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-30 | 8-K/A | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K/A | 3.03 — Material Modification to Rights of Security Holders | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-21 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K/A | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=QNCX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →